Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Extension Study of Enzalutamide in Prostate Cancer
2016-001694-32Phase 2Active
- Sponsor
- Astellas Pharma
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Long-term safety of enzalutamide. Started Sep 2016; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-001694-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001694-32.